Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer

Retargeting of T lymphocytes toward cancer cells by bispecific antibodies has demonstrated its therapeutic potential, with one such antibody approved for the treatment of acute lymphoblastic leukemia (blinatumomab) and several other in clinical trials. However, improvement of their efficacy and sele...

Full description

Bibliographic Details
Main Authors: Antonio Tapia-Galisteo, Íñigo Sánchez Rodríguez, Oscar Aguilar-Sopeña, Seandean Lykke Harwood, Javier Narbona, Mariola Ferreras Gutierrez, Rocío Navarro, Laura Martín-García, Cesáreo Corbacho, Marta Compte, Javier Lacadena, Francisco J. Blanco, Patrick Chames, Pedro Roda-Navarro, Luis Álvarez-Vallina, Laura Sanz
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
trispecific antibodies
single-domain antibodies
scfv
tandem antibodies
cancer immunotherapy
colorectal cancer
Online Access:http://dx.doi.org/10.1080/2162402X.2022.2034355

Internet

http://dx.doi.org/10.1080/2162402X.2022.2034355

Similar Items